Scholarlink

Background <p>Multimodal treatment with preoperative chemotherapy is increasingly used for locally advanced pancreatic cancer (LAPC) to enable surgical resection. However, the optimal time between the last cycle of preoperative chemotherapy and surgery remains unclear. This study aimed to evaluate the association between timing of surgery after preoperative chemotherapy and overall survival of patients with LAPC.</p> Methods <p>Patients with LAPC who underwent pancreatic resection after preoperative chemotherapy between 2018 and 2023 were enrolled from a prospectively maintained database. The cohort was stratified by a predefined interval between the last cycle of chemotherapy and surgery (short interval: &lt; 4&#xa0;weeks vs long interval: ≥ 4&#xa0;weeks).</p> Results <p>After preoperative chemotherapy, 169 patients underwent surgery, including 56&#xa0;(33.1%) patients in the short-interval group and 113 (66.9%)&#xa0;patients in the long-interval group. Baseline characteristics, surgical procedures, and postoperative morbidity were comparable between the two groups. Most patients received FOLFIRINOX (85.5 %) with a median of nine cycles. Patients with the long interval showed significantly improved overall survival from the time of LAPC diagnosis (20.7 vs 29.5&#xa0;months; <i>p </i>= 0.019) as well as from surgery (16.1 vs 23.1&#xa0;months; <i>p </i>= 0.024). In multivariable analysis, the interval of 4&#xa0;weeks or longer was an independent predictor of improved survival. Further analysis suggested an optimal time window of 4–8&#xa0;weeks between the last chemotherapy cycle and surgery.</p> Conclusion <p>An interval of at least 4&#xa0;weeks between the last cycle of preoperative chemotherapy and surgery for LAPC was associated with significantly improved overall survival, with an optimal window of 4–8&#xa0;weeks.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月3日

查看全文
  • Marionna Cathomas,
  • Christoph Kahlert,
  • Thomas Hank,
  • Ingmar Rompen,
  • Maximilian Kryschi,
  • Ulf Hinz,
  • Thilo Hackert,
  • Mohammed Al-Saeedi,
  • Markus W. Büchler,
  • Martin Loos

摘要

Background

Multimodal treatment with preoperative chemotherapy is increasingly used for locally advanced pancreatic cancer (LAPC) to enable surgical resection. However, the optimal time between the last cycle of preoperative chemotherapy and surgery remains unclear. This study aimed to evaluate the association between timing of surgery after preoperative chemotherapy and overall survival of patients with LAPC.

Methods

Patients with LAPC who underwent pancreatic resection after preoperative chemotherapy between 2018 and 2023 were enrolled from a prospectively maintained database. The cohort was stratified by a predefined interval between the last cycle of chemotherapy and surgery (short interval: < 4 weeks vs long interval: ≥ 4 weeks).

Results

After preoperative chemotherapy, 169 patients underwent surgery, including 56 (33.1%) patients in the short-interval group and 113 (66.9%) patients in the long-interval group. Baseline characteristics, surgical procedures, and postoperative morbidity were comparable between the two groups. Most patients received FOLFIRINOX (85.5 %) with a median of nine cycles. Patients with the long interval showed significantly improved overall survival from the time of LAPC diagnosis (20.7 vs 29.5 months; p = 0.019) as well as from surgery (16.1 vs 23.1 months; p = 0.024). In multivariable analysis, the interval of 4 weeks or longer was an independent predictor of improved survival. Further analysis suggested an optimal time window of 4–8 weeks between the last chemotherapy cycle and surgery.

Conclusion

An interval of at least 4 weeks between the last cycle of preoperative chemotherapy and surgery for LAPC was associated with significantly improved overall survival, with an optimal window of 4–8 weeks.